StatPearls Question of the Week – #9

What are present hurdles faced with chimeric antigen receptor-engineered T cells (CAR-T cells) therapy?

A. Antigen loss relapse

B. On target/off tumor toxicity

C. Less efficacy in solid tumors

D. All of the above

Click for the answer and teaching points.